What is the 13F Pro Quality Score for GMED?

13F Pro ranks GLOBUS MEDICAL INC (GMED) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GMED's current score at https://13fpro.ai/company/GMED (free sign-up required for the full ranking).

Which hedge funds own the most GMED stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of GMED include BlackRock,, Jupiter Topco, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/GMED as soon as new 13F filings post.

Where does 13F Pro source GMED data?

All GLOBUS MEDICAL INC fundamentals and ownership data come directly from SEC EDGAR. GLOBUS MEDICAL INC files with the SEC under CIK 1237831. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GMED in?

GLOBUS MEDICAL INC (GMED) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives GMED's revenue?

Per GLOBUS MEDICAL INC's latest 10-Q filed with the SEC on 2026-08-06, the biggest revenue drivers are: Musculoskeletal Solutions ($763.5M); Enabling Technologies ($26.1M). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/GMED.

How often is GMED research updated on 13F Pro?

GMED's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

GLOBUS MEDICAL INC(GMED)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1237831 GMED stock profile & AI dashboard →

13F Pro Quality Score

79.5/100

Rank #37 of 2,961 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

86.8/100

Profitability

79.6/100

Balance Sheet

85.9/100

Earnings Quality

79.1/100

Free Cash Flow

77.6/100

Institutional Flow

88.3/100

Revenue Scale

70.5/100

Dilution Risk

43.3/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why GMED Scores 80/100

exact factor attribution · 2026-09-11

GMED's composite is driven by revenue growth and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+7.4 pts

87th pct

Profitability

+4.4 pts

80th pct

Free cash flow

+4.1 pts

78th pct

Capital efficiency

+3.6 pts

86th pct

Scale

+3.1 pts

71th pct

Earnings quality

+2.9 pts

79th pct

Earnings growth

+2.4 pts

98th pct

Institutional flow

+1.9 pts

88th pct

Shareholder dilution

-0.3 pts

43th pct

Latest change (2026-08-08): 78 → 74 · ↓ Revenue growth 89→64

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

GMED Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for GLOBUS MEDICAL INC (GMED), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GMED at 79.5/100 on a 32-signal composite quality model, placing it at rank #37 of 2,961 stocks — the top 5% of the AI-ranked universe. GMED scores in the top quartile across institutional flow (88.3), revenue growth (86.8), balance sheet strength (85.9). Shareholder dilution risk is elevated at 43.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), GLOBUS MEDICAL INC reports quarterly revenue of $789.6M, net income of $151.6M, an operating margin of 23.1%. Top institutional holders of GMED by reported 13-F value include BlackRock, Jupiter Topco, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. GMED trades on the NYSE exchange and files with the SEC under CIK 1237831. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GMED daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GLOBUS MEDICAL INC directly from SEC EDGAR. GLOBUS MEDICAL INC's 13F Pro composite quality score has ranged between 53 and 82 since 2021, currently 79.5 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about GLOBUS MEDICAL INC

Quirks, history, and lore behind GMED — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · mid-cap · listed on NYSE · headquartered in Pennsylvania.
2
The Numbers
Annual revenue in the range of roughly $1 billion, with a product portfolio spanning hundreds of implant systems sold to hospitals and surgical centers worldwide.
3
The History
Founded in 2003 by a surgeon-entrepreneur who saw a gap in the market for musculoskeletal implants, the company went from startup to NYSE-listed in under a decade.
4
The Secret
It designs nearly all of its products in-house, giving it unusually tight control over both innovation and margins compared with larger orthopedic rivals.
5
The Lore
The company made a big splash by acquiring NuVasive, roughly doubling its scale and making it one of the larger pure-play spine implant companies on the market.
6
The Giveaway
If a surgeon is fusing vertebrae, there's a good chance the hardware came from this spine-focused implant maker whose name evokes a very well-traveled doctor.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving GMED's Business? Latest 10-Q Breakdown

✓ 38/38 datapoints verified

AI-extracted from GLOBUS MEDICAL INC's 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 net sales rose 5.9% to $789.6M and operating income jumped to $182.4M from $76.1M, but net income fell to $151.6M absent last year's $110.6M bargain purchase gain.

Biggest Revenue Drivers

Musculoskeletal Solutions$763.5M

U.S. Musculoskeletal Solutions sales rose $45.7M, driven by spine implantable devices of $32.3M and neuromonitoring of $10.4M; international added $21.2M

Enabling Technologies$26.1M

Domestic Enabling Technology sales decreased $12.3M, driven by lower unit placement; international rose $3.2M on increased unit placement

Biggest Revenue Drivers

Total revenue: $789.6M+5.9% YoY

Musculoskeletal Solutions$763.5M

U.S. Musculoskeletal Solutions sales rose $45.7M, driven by spine implantable devices of $32.3M and neuromonitoring of $10.4M; international added $21.2M

Enabling Technologies$26.1M

Domestic Enabling Technology sales decreased $12.3M, driven by lower unit placement; international rose $3.2M on increased unit placement

Largest Expense Items

Selling, general and administrative$286.8M-5.5% YoY

Decrease of $19.0M in employee-related expenses, partially offset by a $2.7M increase in provision for litigation

Cost of sales (exclusive of amortization of intangibles)$241.4M-2.9% YoY

Prior-year Nevro inventory step-up amortization of $6.0M and $7.3M lower product costs, offset by $3.5M higher freight

Research and development$36.3M-9.1% YoY

Driven by a $4.0M decrease in employee-related expenses

Amortization of intangibles$29.6M-2.1% YoY

Primarily driven by the finalization of amortization of intangible assets

Margins: Cost of sales fell to 30.6% of net sales from 33.4%, and SG&A to 36.3% from 40.7%, lifting operating income to $182.4M from $76.1M.

Watch Items from the Filing

Enabling Technologies net sales fell to $26.1M from $35.2M; domestic Enabling Technology sales dropped $12.3M on lower unit placement.
U.S. net sales grew only 3.0% to $619.1M while international grew 18.0% to $170.5M; U.S. Nevro sales declined $15.1M.
Pimenta litigation: November 2025 jury verdict of $28.7M in damages; $43.1M liability accrued at December 31, 2025, with appeal filed.
Effective tax rate rose to 20.1% from (7.8%), reflecting prior-period state valuation allowance release and non-taxable bargain purchase gain.
Repurchased 1.6 million shares for $136.1 million at an average $82.96; $253.9 million remains authorized, with no borrowings under the $400.0 million facility.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$789.6M

Net Income

Q2 2026

$151.6M

Free Cash Flow

Q2 2026

$176.6M

Operating Margin

Q2 2026

23.1%

ROIC

Q2 2026

15.3%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+16.7% YoY

$2.94BFY 2025

FY22 $1.02BFY23 $1.57BFY24 $2.52BFY25 $2.94B

Net Income

+422.3% YoY

$537.9MFY 2025

FY22 $190.2MFY23 $122.9MFY24 $103.0MFY25 $537.9M

Operating Income

+189.1% YoY

$479.8MFY 2025

FY22 $228.0MFY23 $133.1MFY24 $166.0MFY25 $479.8M

EPS (Diluted)

+422.7% YoY

$3.92FY 2025

FY22 $1.85FY23 $1.07FY24 $0.75FY25 $3.92

Total Assets

+1.0% YoY

$5.30BFY 2025

FY22 $2.08BFY23 $5.09BFY24 $5.25BFY25 $5.30B

Op. Cash Flow

+44.7% YoY

$753.4MFY 2025

FY22 $178.5MFY23 $243.5MFY24 $520.6MFY25 $753.4M

Free Cash Flow

+45.3% YoY

$588.8MFY 2025

FY22 $104.4MFY23 $165.2MFY24 $405.2MFY25 $588.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$2.94B +16.7%	$2.52B +60.6%	$1.57B +53.3%	$1.02B +6.8%	$958.1M +21.4%	$789.0M
Net Income	$537.9M +422.3%	$103.0M -16.2%	$122.9M -35.4%	$190.2M +27.5%	$149.2M +45.9%	$102.3M
Operating Income	$479.8M +189.1%	$166.0M +24.7%	$133.1M -41.6%	$228.0M +32.6%	$172.0M +54.3%	$111.4M
EPS (Diluted)	$3.92 +422.7%	$0.75 -29.9%	$1.07 -42.2%	$1.85 +28.5%	$1.44 +42.6%	$1.01
Total Assets	$5.30B +1.0%	$5.25B +3.3%	$5.09B +145.0%	$2.08B +6.1%	$1.96B +16.5%	$1.68B
Operating Cash Flow	$753.4M +44.7%	$520.6M +113.8%	$243.5M +36.4%	$178.5M -35.4%	$276.3M +39.0%	$198.8M
Free Cash Flow	$588.8M +45.3%	$405.2M +145.2%	$165.2M +58.2%	$104.4M -52.4%	$219.4M +62.3%	$135.1M

Get alerted when GMED's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for GLOBUS MEDICAL INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GMED

BlackRock, Inc.
$853.8M10,806,724 sh
Jupiter Topco LLC
$647.9M8,200,423 sh
VANGUARD CAPITAL MANAGEMENT LLC
$403.5M5,107,532 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$394.6M4,994,385 sh
Invesco Ltd.
$340.5M4,309,771 sh
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC
$338.1M4,279,730 sh
STATE STREET CORP
$293.5M3,714,029 sh
Sculptor Capital LP
$237.0M3,000,000 sh
JPMORGAN CHASE & CO
$230.8M2,743,850 sh
ALLIANCEBERNSTEIN L.P.
$205.1M2,380,344 sh

Fund	Value	Shares
BlackRock, Inc.	$853.8M	10,806,724
Jupiter Topco LLC	$647.9M	8,200,423
VANGUARD CAPITAL MANAGEMENT LLC	$403.5M	5,107,532
VANGUARD PORTFOLIO MANAGEMENT LLC	$394.6M	4,994,385
Invesco Ltd.	$340.5M	4,309,771
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC	$338.1M	4,279,730
STATE STREET CORP	$293.5M	3,714,029
Sculptor Capital LP	$237.0M	3,000,000
JPMORGAN CHASE & CO	$230.8M	2,743,850
ALLIANCEBERNSTEIN L.P.	$205.1M	2,380,344

Companies Similar to GMED

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

STE

STERIS plc

AI score

Similar quality profile · 15 shared holders

Boston Partners Boston Trust Walden Corp Swedbank AB

BSX

BOSTON SCIENTIFIC CORP

AI score

Similar quality profile · 11 shared holders

Capital World Investors Holocene Advisors, LP Swedbank AB

NBIX

NEUROCRINE BIOSCIENCES INC

AI score

Similar quality profile · 20 shared holders

Vestal Point Capital, LP Swedbank AB FULLER & THALER ASSET MANAGEMENT, INC.

MEDP

Medpace Holdings, Inc.

AI score

Similar quality profile · 26 shared holders

FULLER & THALER ASSET MANAGEMENT, INC.Boston Trust Walden Corp Stephens Investment Management Group LLC

BCPC

BALCHEM CORP

AI score

Similar quality profile · 13 shared holders

GENEVA CAPITAL MANAGEMENT LLC WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Stephens Investment Management Group LLC

INCY

INCYTE CORP

AI score

Similar quality profile · 7 shared holders

Swedbank AB Grantham, Mayo, Van Otterloo & Co. LLC Bridgewater Associates, LP

RMD

RESMED INC

AI score

Similar quality profile · 14 shared holders

AMERICAN CAPITAL MANAGEMENT INC Swedbank AB Capital Impact Advisors, LLC

JAZZ

Jazz Pharmaceuticals plc

AI score

Similar quality profile · 17 shared holders

Boston Trust Walden Corp WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC FULLER & THALER ASSET MANAGEMENT, INC.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GMED on your watchlist

Track score changes the day GLOBUS MEDICAL INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GMED a good stock to buy?

13F Pro's AI-powered analysis of GLOBUS MEDICAL INC (GMED) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GMED are available on the GMED stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. GMED is classified as a mid company.

Which hedge funds own GMED?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GMED. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GLOBUS MEDICAL INC's investment landscape.